ACSL4 and metabolic dysfunction-associated steatotic liver disease: It is worth mentioning that previous research has suggested a targeting gene acyl-CoA synthetase long-chain family member 4 (Acsl4), which could potentially offer an alternative therapeutic approach for MASLD [36].